JoVE Logo

Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Minimal erythema dose (MED) testing is used to establish dosage schedules for ultraviolet radiation phototherapy. It can assess individual variation in inflammatory response but lacks methodology for achieving reproducible results. Here, we present a precision implementation of MED and demonstrate its ability to capture individual variation in inflammatory response.

Abstract

Minimal erythema dose (MED) testing is frequently used in clinical settings for determining the smallest amount of ultraviolet (UV) irradiation necessary to produce erythema (inflammatory reddening) on the surface of the skin. In this context, the MED is regarded as a key factor in determining starting doses for UV phototherapy for common skin conditions such as psoriasis and eczema. In research settings, MED testing also has potential to be a powerful tool for assessing within- and between-persons variation in inflammatory responses. However, MED testing has not been widely adopted for use in research settings, likely owing to a lack of published guidelines, which is a barrier to obtaining reproducible results from this assay. Also, protocols and equipment for establishing MED vary widely, making it difficult to compare results across laboratories. Here, we describe a precise and reproducible method to induce and measure superficial erythema using newly designed protocols and methods that can easily be adapted to other equipment and laboratory environments. The method described here includes detail on procedures that will allow extrapolation of a standardized dosage schedule to other equipment so that this protocol can be adapted to any UV radiation source.

Introduction

Minimal erythema dose (MED) testing is an FDA-approved procedure to evaluate cutaneous sensitivity to radiation typically in the UVB range, although the MED can be determined at other wavelengths in the UV and visible spectrum1. Erythema is defined as superficial reddening on the surface of the skin caused by engorgement of capillaries (later stages of erythema are more commonly known as sunburn). MED testing has been used extensively in the dermatology literature and clinical phototherapy settings to identify the minimal amount of ultraviolet (UV) radiation that will produce the smallest unit of measurable change in the redness of the skin. MED testing can be accomplished with a commercially available UV lamp, equivalent to what is used in most commercial tanning facilities.

MED testing involves continuous dispersal of UV radiation or light from the visible spectrum onto the surface of the skin for a predetermined length of time, with dosage schedules depending primarily on pigmentation of the skin and the intensity and type of radiation. This procedure is commonly used in clinical settings to determine dosage schedules for patients receiving UV radiation therapy for skin conditions such as psoriasis and eczema2,3. Basic procedures for determining the MED in clinical settings have been described elsewhere4, and can be used to adjust the total dosage of UV radiation upward or downward, depending on individual variation in skin sensitivity.

Skin pigmentation is perhaps the most important subject-specific variable in conducting and measuring results from the MED procedure6. This is because the duration of UV exposure required to evoke the minimal erythema response is principally determined by the lightness or darkness of the participant’s skin, as defined by the participant’s Fitzpatrick skin type (FST). FST7 is a numerical scheme for classifying human skin color. The Fitzpatrick scale is a recognized tool for dermatological research into human skin pigmentation8,9, and classifies human skin into one of six categories from lightest (FST I) to darkest (FST VI).

Darker FST typologies require longer UV duration, therefore accurate classification of FST is important. There is an extensive literature on methods for accurate assessment of FST, using a wide variety of approaches including self-report, dermatologist interview and instrumentation-based assessment. Observer ratings of FST have been shown to be correlated with current, but not natural skin color10, however FST can be determined subjectively11 using self-report via questionnaire12 and/or objective assessment via spectrophotometry. Fitzpatrick typing by spectrophotometry has been shown to correlate closely to participant self-report in a number of studies10,13,14,15.

Despite the utility and widespread use of MED testing in clinical services, this procedure has not been widely adopted in laboratory settings for measurement of individual variation in response to pro-inflammatory stimulation. The purpose of the methodology outlined here is to provide techniques and step-by-step procedures that increase the precision and reproducibility of the MED testing procedure, in order to facilitate future work in laboratory settings focused on fine-grained quantification of intra-individual variability in inflammatory response. We further provide representative results that illustrate the capability of this standardized protocol to accurately capture person-to-person variation in inflammation.

Protocol

All methods described below including the use of human volunteers have been reviewed and approved by the local Institutional Review Board (IRB), and are in accordance with the Declaration of Helsinki and Belmont Report. All participants (N=72) signed informed consent as proscribed by the IRB protocol. Inclusion/exclusion criteria and discontinuation procedures were designed to maximize participant safety, and any deviation from these procedures should be considered in light of their impact on risk and tolerability to human subjects. In the context of the work presented here, the exclusionary criteria restricted participation to individuals with no personal or family history of inflammatory conditions, or any licit or illicit substances. The justification for doing so is that these factors may influence responses to the MED testing procedure.

1. Participant Selection

  1. Use the following inclusion criteria: 18-55 years old; in good general health as determined by Medical Symptom Checklist (MSCL)5; can understand and communicate about the lab safety protocol presented in English; can provide written consent.
  2. Use the following exclusion criteria: Fitzpatrick skin type I, as determined by self-report; uses commercial tanning equipment regularly; skin wounds or lesions at the planned site of exposure; current skin cancer, or personal history of skin cancer; family history of skin cancer; diabetes; psoriasis or other inflammatory skin condition; peripheral vascular disease, peripheral arterial disease, Raynaud's disease, or any other diagnosed circulatory disorders; any involuntary motor disorders; allergic to adhesive tape; takes inhaled steroids for asthma (e.g., Fluticasone); takes any corticosteroids; 2 or more of the following (diagnosed hypertension, hyperlipidemia, high cholesterol, smoke cigarettes, family history of coronary or atherosclerotic disease (parents/siblings prior to age 55)); active substance dependence - legal or illicit; people with substance dependence new to recovery (less than one year); use of medications that affects CNS function, including psychotropics, opiate medication or corticosteroids, during the last 3 months; any prescribed psychotropic medications, currently or during the last 3 months (These include medications for anxiety, depression, or other psychological problems).

2. Scheduling and Preparation for the MED

  1. Schedule participants for two appointments: the first, the MED exposure event (approximately 45 min), and the second, a follow-up to gather spectrophotometry readings (approximately 10 min). Schedule the follow-up appointment for 24 h subsequent to the first appointment.
  2. Before participants arrive, lay out and set up essential equipment including two dose testing cuffs and safety equipment. Have a variety of UV-protective clothing (such as UV-protective sports sleeves, UV-protective gloves, long sleeve medical scrubs, UV-protective sheets and tape to affix the sheets) for both the participant and the researcher to cover all skin exposed to UV radiation.
  3. Calibrate the spectrophotometer according to manufacturer specifications. Do this for each subject and each session.

3. Determining Fitzpatrick Skin Type (FST)

  1. When the participant arrives for the MED exposure event (Visit 1), identify FST either through self-report or spectrophotometry. To maximize participant safety, do not conduct MED testing on participants categorized as FST 1. For all other Fitzpatrick Skin Types (2—6), use the FST score to determine which exposure schedule should be used.

4. Cuff 1 Application

  1. Explain to the participant how MED testing works and solicit questions before proceeding.
  2. Generally, perform the MED procedure on the inside of the non-dominant forearm.
  3. Place Cuff 1 (with all aperture coverings removed) avoiding freckles, moles, scars, hair (to the extent possible), and any cuts, bruises or lesions on the skin. Remove only the protective wax paper backing from the lateral (not central) portions of Cuff 1. It is important that the wax paper backing from the central portion of Cuff 1 not be removed, as the adhesive has a strong potential to irritate the skin when peeled off after baseline readings, causing reddening of skin proximal to the apertures.
  4. After situating Cuff 1 at the intended exposure site, place landmarks using a permanent marker to ensure that Cuff 2 will be situated at precisely the same location. Mark the skin at four points outside of the creases of each of the side flaps of Cuff 1, the upper right, upper left, lower right and lower left points.
    1. Make these marks dark enough to survive approximately 24 h, as they will also be used to place Cuff 3 in precisely the same location at the follow-up appointment 24 h later.

5. Baseline Reading: Cuff 1 Application

  1. Using a spectrophotometer that has been calibrated according to manufacturer specifications, obtain and permanently record readings at each of the six open apertures in sequence.
  2. Ensure that the spectrophotometer is placed the center of the cuff apertures while avoiding moles, scars, or other blemishes to the extent possible.
  3. Permanently record all “SCI” values (L, A, B). To ensure consistent readings with the same calibration point, keep the spectrophotometer in the ON for the duration of the MED procedure and do not turn off until the post-exposure readings have been completed.
  4. After baseline spectrophotometry measurements have been recorded, remove Cuff 1. To minimize participant discomfort, apply medical adhesive solvent to the perimeter of Cuff 1 as it is peeled off, which will prevent painful removal of hair on the arm.

6. Pre-exposure Reading: Cuff 2 Application

  1. After removal of Cuff 1, situate Cuff 2 at the same location using the landmarks drawn on the skin for Cuff 1. The full adhesive backing may be exposed and applied to ensure that Cuff 2 is sufficiently sealed to prevent cross exposure among apertures due to insufficient adhesion to the skin.
  2. Have both the participant and the researcher don UV-protective clothing and safety accessories. At minimum, the participant, the technician administering the procedure and any other parties in the room must don UV-protective glasses. Technicians should wear long sleeves or use a UV-protective sleeve.
  3. Prior to activating the lamp, have the technician assist the participant in covering all exposed skin, including the arm above the patch, the arm and wrist below the patch, the hand, and parts of the front or back of the arm that may be exposed on the sides of the patch (UV-protective sheets and tape to affix the sheets may be helpful for this). Additionally, some participants wearing shirts with open necklines may want to drape UV-protective cloth over their neck and chest if these areas will be close to the UV source.
  4. Spread a UV-protective cloth under the participant’s arm (to reduce reflectance off the table surface).

7. MED Procedure: Pre-exposure

NOTE: The rays from the lamp must be perpendicular to the exposure site. In general, physical movement of the lamp is less possible than movement or arrangement of the angle of participants’ arm.

  1. Prior to activating the lamp, arrange the participant’s arm such that the UV rays from the lamp will be perpendicular to the angle of Cuff 2 on the participant’s arm.
  2. Identify the proper distance between the lamp and Cuff 2 on the participant’s arm. Place the radiometer’s sensor facing the UV lamp parallel to the surface of the skin and as close as possible to the location of Cuff 2.
  3. Cover the participants arm with a UV proof cloth to prevent exposure, and briefly activate the lamp to adjust the distance to Cuff 2 until the radiometer’s sensor reads 270 μW/cm2.
    1. To achieve this reading, adjust the distance between the lamp and the surface of the skin until the radiometer reads 270 μW/cm2 (± 10 μW). Once the proper distance has been determined, deactivate the lamp.
      NOTE: It is important to note here that small differences in the angle of the radiometer will greatly affect the reading. Thus, the angle of the radiometer should be as close to parallel to the surface of the skin as possible.
  4. Make further adjustments in distance throughout the exposure session to prevent drift in the location of the arm. At each reading, confirm the distance and readjust as necessary to maintain radiometer readings at approximately 270 μW/cm2 (± 10 μW).

8. MED Procedure: Exposure

  1. Use a stopwatch to implement the MED schedule. Remove the first aperture covering before activating the UV source. Activate the source and the stopwatch simultaneously and remove each aperture covering on Cuff 2 according to the schedule specified below, based on FST.
  2. At the point of removal for each aperture covering, record the radiometer reading when the radiometer is held parallel to the surface of the skin and pointed at the lamp. If the distance has changed, adjust the distance to lamp to ensure that the radiometer once again reads 270 (± 10) μW/cm2.
  3. Have the technician monitor the participant’s arm to ensure consistent positioning. In particular, readjust the arm if the arm rotates, as many participants will rotate the arm as they relax. Subsequent to any adjustments, re-confirm that the radiometer reads 270 μW/cm2 (± 10 μW).
  4. Turn off the lamp at precise time specified by the dosage schedule in Table 1. Do not deactivate the stopwatch, as an additional series of spectrophotometer readings should be gathered exactly 7 minutes subsequent to deactivation of the lamp, as described below.

9. 7 Min Post-exposure Reading

  1. Exactly 7 minutes subsequent to the deactivation of the lamp, record the final spectrophotometer readings from each aperture in Cuff 2. The purpose in collecting data immediately subsequent to the exposure procedure is to first confirm no adverse reaction to the UV radiation, and second to evaluate initial responses, which in some cases can be slight, but measurably different from baseline (pre-exposure) values. Any increase in redness after 7 minutes is likely to be a thermal effect and not erythema.
    NOTE: An adverse reaction to UV radiation exposure after 7 minutes is likely related to the minimal urticarial dose of solar urticaria, an acquired photosensitivity disorder. Photosensitivity disorders are assessed prior to the MED procedure and subjects with these disorders should be ruled out. However, if this is observed at any point during testing the exposure protocol should be discontinued immediately.
  2. After exposure to UV radiation, Cuff 2 can be particularly difficult to remove. Use medical-grade adhesive solvent, if necessary, to minimize discomfort to participants during removal of Cuff 2. Participants with particularly hirsute or otherwise sensitive skin may find it helpful to apply either olive oil or alcohol-based adhesive remover under the edge of Cuff 2, as they remove the patch slowly. After Cuff 2 is removed participants may have residual adhesive on their skin, which can also be removed with either olive oil or medical adhesive solvent.
  3. Prior to departure from the exposure session, remind participants not to wash the landmarks and not apply any lotions to the exposure site.

10. Follow-up Appointment: Cuff 3 Application

  1. Before the participant arrives, calibrate the spectrophotometer according to manufacturer specifications.
  2. Prepare Cuff 3 by removing all of the aperture coverings (leaving the white wax paper backing on the central portion of the patch). When placing Cuff 3 on the participant’s arm, remove the white wax paper backing from the two side flaps of the patch. Using the landmarks on the participant’s forearm, place Cuff 3 in the same location as the previous two patches.
  3. Take a reading at each of the six open apertures in sequence. Additionally, visually inspect each aperture and record whether there appears to be visual evidence of an erythema response in each of the six apertures (red or pink skin indicates erythema). After permanently recording spectrophotometer readings, remove Cuff 3, using solvent if necessary.
  4. To further enhance participant comfort and safety, provide 4-6 single-use burn gel or aloe vera, and indicate to the participant that if the exposure site becomes itchy or uncomfortable, it may be treated like a sunburn with these or similar over the counter products.

Results

The timing schedule presented in Table 1 is a novel dosage schedule that was calculated to capture the MED, on average, at the mid-point of the exposure event (i.e., aperture 3 or 4) for each FST. The basis for the calculated schedule is as follows.

Prior work has established that for individuals with FST 2, the median MED for radiation in the UVB range is 66.9 milliwatts (mW) per cm2, 77.429 mW/cm2 for FST 3 and 85.0 for FST 416. ...

Discussion

Precision implementation of MED testing as described here could offer several advantages over other extant lab-based inflammatory challenges that have achieved popular use. For example, suction blister protocols17,18,19 raise a fluid-filled blister on the skin that is subsequently aspirated with a syringe to gain direct access to the cytokine microenvironment. Although skin blistering is a well-known tool for studying skin immun...

Disclosures

The authors on this study declare no conflicts of interest, financial or otherwise.

Acknowledgements

This work was supported by a grant from the Virginia Tech College of Science Discovery Fund.

Materials

NameCompanyCatalog NumberComments
6-aperture dose testing patch (“Cuff”)Daavlin  
Medical grade adhesive solvent
Non-reflective UV proof cloth
RadiometerSolarLightModel 6.2 UVB Meter
Single use aloe or burn gel
SpectrophotometerKonika-MinoltaCM-2600D
Stopwatch
UV lamp – Fiji SunSpertiEmission spectrum 280 nm-400 nm, approximately 25% UVB
UV-proof safety glasses (2 pair)
UV-proof sleeve
White cotton gloves (2 pair)

References

  1. Magnus, I. A. Dermatological Photobiology: Clinical and Experimental Aspects. Blackwell Scientific Publications. , (1976).
  2. Grundmann-Kollmann, M., et al. Phototherapy for atopic eczema with narrow-band UVB. Journal of the American Academy of Dermatology. 40 (6), 995-997 (1999).
  3. Honigsmann, H. Phototherapy for psoriasis. Clinical and Experimental Dermatology. 26 (4), 343-350 (2001).
  4. Heckman, C. J., et al. Minimal Erythema Dose (MED) testing. Journal of Visualized Experiments. (75), e50175 (2013).
  5. Kroenke, K., et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Archives of Family Medicine. 3 (9), 774-779 (1994).
  6. Coelho, S. G., et al. Non-invasive diffuse reflectance measurements of cutaneous melanin content can predict human sensitivity to ultraviolet radiation. Experimental Dermatology. 22 (4), 266-271 (2013).
  7. Fitzpatrick, T. B. The validity and practicality of sun-reactive skin types I through VI. Archives of Dermatology. 124 (6), 869-871 (1988).
  8. Matts, P. J., Dykes, P. J., Marks, R. The distribution of melanin in skin determined in vivo. British Journal of Dermatology. 156 (4), 620-628 (2007).
  9. Eilers, S., et al. Accuracy of self-report in assessing Fitzpatrick skin phototypes I through VI. JAMA Dermatology. 149 (11), 1289-1294 (2013).
  10. Daniel, L. C., Heckman, C. J., Kloss, J. D., Manne, S. L. Comparing alternative methods of measuring skin color and damage. Cancer Causes, Control. 20 (3), 313-321 (2009).
  11. Ravnbak, M. H., Philipsen, P. A., Wulf, H. C. The minimal melanogenesis dose/minimal erythema dose ratio declines with increasing skin pigmentation using solar simulator and narrowband ultraviolet B exposure. Photodermatology Photoimmunology & Photomedicine. 26 (3), 133-137 (2010).
  12. Miller, S. A., et al. Evidence for a new paradigm for ultraviolet exposure: a universal schedule that is skin phototype independent. Photodermatology Photoimmunology & Photomedicine. 28 (4), 187-195 (2012).
  13. Pershing, L. K., et al. Reflectance spectrophotometer: The dermatologists' sphygmomanometer for skin phototyping. Journal of Investigative Dermatology. 128 (7), 1633-1640 (2008).
  14. Kollias, N., Baqer, A., Sadiq, I. Minimum Erythema Dose Determination in Individuals of Skin Type-V and Type-Vi with Diffuse-Reflectance Spectroscopy. Photodermatology Photoimmunology & Photomedicine. 10 (6), 249-254 (1994).
  15. Treesirichod, A., Chansakulporn, S., Wattanapan, P. Correlation Between Skin Color Evaluation by Skin Color Scale Chart and Narrowband Reflectance Spectrophotometer. Indian Journal of Dermatology. 59 (4), 339-342 (2014).
  16. Gambichler, T., et al. Reference limits for erythema-effective UV doses. Photochemistry and Photobiology. 82 (4), 1097-1102 (2006).
  17. Kool, J., et al. Suction blister fluid as potential body fluid for biomarker proteins. Proteomics. 7 (20), 3638-3650 (2007).
  18. Clark, K. E., Lopez, H., Abdi, B. A., et al. Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis. Arthritis Research & Therapy. 17, 73 (2015).
  19. Rosenkranz, M. A., et al. A comparison of mindfulness-based stress reduction and an active control in modulation of neurogenic inflammation. Brain Behavior and Immunity. 27 (1), 174-184 (2013).
  20. Smith, T. J., Wilson, M. A., Young, A. J., Montain, S. J. A suction blister model reliably assesses skin barrier restoration and immune response. Journal of Immunological Methods. 417, 124-130 (2015).
  21. Holm, L. L., et al. A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo. Journal of Visualized Experiments. (138), 57554 (2018).
  22. Seitz, J. C., Whitmore, C. G. Measurement of erythema and tanning responses in human skin using a tri-stimulus colorimeter. Dermatologica. 177 (2), 70-75 (1988).
  23. Henriksen, M., Na, R., Agren, M. S., Wulf, H. C. Minimal erythema dose after multiple UV exposures depends on pre-exposure skin pigmentation. Photodermatology Photoimmunology & Photomedicine. 20 (4), 163-169 (2004).
  24. Stamatas, G. N., Zmudzka, B. Z., Kollias, N., Beer, J. Z. In vivo measurement of skin erythema and pigmentation: new means of implementation of diffuse reflectance spectroscopy with a commercial instrument. British Journal of Dermatology. 159 (3), 683-690 (2008).
  25. Latreille, J., et al. Influence of skin colour on the detection of cutaneous erythema and tanning phenomena using reflectance spectrophotometry. Skin Research and Technology. 13 (3), 236-241 (2007).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Minimal Erythema DoseMED TestingErythemaInflammatory ResponsePrecision DosingDermatological PhototherapyCalibrated SpectrophotometerSkin MarkingsReproducibility Of ResultsInflammation ExaminationParticipant ProcedureSafety Equipment

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved